Drug intelligence / Profile preview

VYR-103

Development stage: Preclinical
Lead developer: VaRi Bioscience
Modality: Hydrogel Systems → Drug Delivery Systems

Overview

VYR-103 is a preclinical-stage therapeutic candidate being developed by Vyripharm International for the treatment of epilepsy. The drug utilizes a hydrogel-based drug delivery system, which is designed to provide controlled or sustained release of the active pharmaceutical ingredient. Vyripharm International focuses on integrating bioinformatics, diagnostic imaging, and personalized medicine, often utilizing cannabinoid-based platforms, although the specific active component of VYR-103 has not been publicly disclosed. The program is currently in the preclinical phase of development.

Beyond the preview

Go deeper on VYR-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-103.

Explore the full profile